Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T18:22:57.015Z.
Calculation as of: 2026-10-06T18:22:57.015Z.
Quote observation: 2026-10-06T18:19:04.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 108f8fd7c16ea3ee173cf4c928fb1762d5fda8f0ed14c05de6879cdcb1b92349
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Sonoma Pharmaceuticals, Inc.
Market Cap
$5.79M
EBITDA Yield
N/A
| NAME | MARKET CAP | EBITDA YIELD |
|---|---|---|
| Sonoma Pharmaceuticals, Inc. (SNOA) | $5.79M | N/A |
| Lucyd, Inc (LUCY)vs › | $5.86M | N/A |
| enVVeno Medical Corporation (NVNO)vs › | $5.70M | N/A |
| Scienture Holdings, Inc. (SCNX)vs › | $5.94M | N/A |
| Cardio Diagnostics Holdings, Inc. (CDIO)vs › | $5.89M | N/A |
| Enlivex Therapeutics Ltd. (ENLV)vs › | $5.89M | N/A |
| Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)vs › | $5.58M | N/A |
| Acurx Pharmaceuticals, Inc. (ACXP)vs › | $5.59M | N/A |
| Soligenix, Inc. (SNGX)vs › | $5.34M | N/A |
| Femasys Inc. (FEMY)vs › | $6.28M | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
